Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Baiba I Berzins"'
Autor:
Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, ACTG A5262 Study Team, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, Amy Jennings
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90485 (2014)
The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluated Illumina
Externí odkaz:
https://doaj.org/article/bb218b722bfe4aa0a28c5e7a7e8619e1
Autor:
Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, ACTG A5262 Study Team, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, Amy Jennings
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 3, p e90485 (2014)
PLoS ONE, Vol 9, Iss 3, p e90485 (2014)
Background The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluate